Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A-dmDT390-bisFv(UCHT1) |
Synonyms | |
Therapy Description |
Resimmune (A-dmDT390-bisFv(UCHT1)) comprises the diphtheria toxin catalytic and translocation domains fused to antibody fragments that target the CD3-epsilon component of the T-cell receptor, potentially resulting in increased death of CD3-epsilon expressing tumor cells (PMID: 25795722) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
A-dmDT390-bisFv(UCHT1) | anti-T cell immunotoxin A-dmDT390-bisFv(UCHT1)|Resimmune | Resimmune (A-dmDT390-bisFv(UCHT1)) comprises the diphtheria toxin catalytic and translocation domains fused to antibody fragments that target the CD3-epsilon component of the T-cell receptor, potentially resulting in increased death of CD3-epsilon expressing tumor cells (PMID: 25795722) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|